I'm not surprised to hear that the S-1 was approved back in January. There just wasn't any hard evidence in favor of a decline. The fact that it hasn't been posted officially also doesn't surprise me. I'm sure GS has found some minor technicality to stall the SEC from publishing it.
...which leads me to believe that GS is prepping for a very determined re-entry with a deal that not even his angriest opponents will be able to derail.
I'm of the belief that GS (with the advise of his Israeli partners) orchestrated an ugly scenario to achieve two goals. First, they had to get rid of the unruly OTC retail shareholders/flippers. They had become a liability for any deal and had to go. So far it appears by the reduced number of messages on this board and others that he's removed the undesirables. Second, he's opened up his SPAC to the would be investors to pick up some cheap shares. As DrugDoctor noted on the SRNW board recently, the accumulation numbers for SRNW have increased notably in the past few weeks. By redistributing shares from weak hands to stronger ones, GS can close an awesome deal, especially with SRNW, since its float is a mere 50m shares. Any rise in SRNW will also affect FORW.
JMHO